title: Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma.
abstract: Prostatic acid phosphatase (PAP) is one of the prostate-related antigens that are applicable to specific immunotherapy for patients with prostate cancer. In this study, we determined whether or not PAP could be a target molecule in specific immunotherapy for patients with nonprostate cancer. A variety of adenocarcinoma cell lines were examined for their PAP expression at the mRNA and protein levels by reverse transcription polymerase chain reaction and western blot analysis, respectively. Considerable percentages of colon, gastric, and breast cancer cell lines were found to be positive for PAP at both the mRNA and the protein levels. The PAP expression in cancer tissues was also confirmed by immunohistochemical staining. In addition, we examined whether cancer-reactive cytotoxic T lymphocytes (CTLs) could be induced from peripheral blood mononuclear cells (PBMCs) of human leukocyte antigen (HLA) A24+ nonprostate cancer patients by in vitro stimulation with a PAP peptide. As a result, tumor-specific CTLs could be induced from the PBMCs of HLA-A24+ colon and gastric cancer patients. Their cytotoxicity against HLA-A24+ cancer cells was dependent on PAP peptide-specific and CD8+ T cells. These findings indicate that PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.
authors.affiliation: Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan.
authors.forename: Yi
authors.initials: Y
authors.lastname: Wang
authors.forename: Mamoru
authors.initials: M
authors.lastname: Harada
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Yano
authors.forename: Sachiko
authors.initials: S
authors.lastname: Ogasawara
authors.forename: Hiroko
authors.initials: H
authors.lastname: Takedatsu
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Arima
authors.forename: Satoko
authors.initials: S
authors.lastname: Matsueda
authors.forename: Akira
authors.initials: A
authors.lastname: Yamada
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
mesh_terms: D000135:Acid Phosphatase; D000230:Adenocarcinoma / Q000097:blood / Q000201:enzymology* / Q000235:genetics; D001943:Breast Neoplasms / Q000097:blood / Q000201:enzymology / Q000235:genetics; D045744:Cell Line, Tumor / Q000201:enzymology* / Q000276:immunology; D003110:Colonic Neoplasms / Q000097:blood / Q000201:enzymology / Q000235:genetics; D005260:Female; D005753:Gastric Mucosa / Q000201:enzymology; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D015234:HLA-A Antigens / Q000276:immunology; D059871:HLA-A24 Antigen; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D010455:Peptides / Q000494:pharmacology; D017027:Protein Tyrosine Phosphatases / Q000032:analysis / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013274:Stomach Neoplasms / Q000097:blood / Q000201:enzymology / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D010455:Peptides; D012333:RNA, Messenger; D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases